ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0113

Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease
Abstract Number: 1243

Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry
Abstract Number: 1884

Real-life Data for the Use of Anti-TNF Treatment in DADA2
Abstract Number: 1818

Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 0129

Real-World Flare Rates and Progression by Treatment Settings Among the Commercially-Insured Systemic Lupus Erythematosus Population in the U.S
Abstract Number: 0586

Recommended Fiber Intake, but Not Overall Dietary Quality, Is Associated with Reduced Risk of Rheumatoid Arthritis – Results from a Nested Case-control Study
Abstract Number: 0788

Red Cell Distribution Width Is Associated with Baseline 25-hydroxyvitamin D Level Before Methotrexate Therapy in Rheumatoid Arthritis
Abstract Number: 1826

Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis
Abstract Number: 0231

Reducing the Number of Outpatient Clinic Visits by Using the Routine Assessment of Patient Index Data 3 as a Screening Tool
Abstract Number: 1283

Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies
Abstract Number: 1737

Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
Abstract Number: 1427

Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis
Abstract Number: 1790

Regional Differences in Clinical Characteristics and Treatment of Psoriatic Arthritis with Axial Involvement: Results from the Cross Sectional International ASAS PerSpA Study
Abstract Number: 0850

Regression Methods for Modeling Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Scores for Early Stage Knee Osteoarthritis
Abstract Number: 1584

Relation of Depressive Symptoms to Alterations in Conditioned Pain Modulation in Knee Osteoarthritis: The Multicenter Osteoarthritis Study (MOST)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].